Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Best Infectious Disease News Delivered Weekly

The Contagion® Prevention specialty page provides infection prevention-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

PREVENTION VIDEOS - Page 4

Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy
Peter L. Salgo, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); Jason Pogue, PharmD, BCPS-AQID; Andrew Shorr, MD; and Debra Goff, PharmD, FCCP, reflect on the caveats in lipoglycopeptide therapy for gram-positive nosocomial infections and emphasize that this is a different, not overarchingly effective, class of drugs.
Selecting Lipoglycopeptide Therapy for Gram-Positive NIs
Peter L. Salgo, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); and Debra Goff, PharmD, FCCP, share insight on selecting the appropriate agent in the setting of lipoglycopeptide therapy for gram-positive nosocomial infections regarding dosing, mechanisms of action, and patient populations.
Understanding Gram-Positive Nosocomial Infections
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; Debra Goff, PharmD, FCCP; Andrew Shorr, MD; and Sandy J. Estrada Lopez, PharmD, BCPS (AQID), give considerations for gram-positive nosocomial infections, including how to identify risk and the prevalence of methicillin-resistant Staphylococcus aureus in this setting.
Gram-Negative NIs: Vabomere and the TANGO II Study
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; and Andrew Shorr, MD, discuss the recent approval of Vabomere, a combination of meropenem and vaborbactam, in the setting of gram-negative nosocomial infections based on the positive study results of the TANGO II trial.
<i>Pseudomonas</i> Infections in the ICU: Who's Susceptible?
Peter L. Salgo, MD; Marin Hristos Kollef, MD; Jason Pogue, PharmD, BCPS-AQID; Yoav Golan, MD; and Andrew Shorr, MD, identify which patients are most susceptible to Pseudomonas infections and address the settings in which risk for infection is greatest.
<i>C. difficile</i> Rates in the United Kingdom
Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.
Incorporating Technology into Antimicrobial Stewardship Programs
Debra Goff, PharmD, FCCP, explains how technology can be incorporated into antimicrobial stewardship programs.
High-Touch Points in Hospital Rooms That Harbor Pathogenic Bacteria
Barley Chironda, RPN, CIC, discusses different high-touch surfaces in hospital rooms that are known to harbor pathogenic bacteria.
FEATURED
Big advances in treatment can